Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation

Breast Cancer Research and Treatment

Volumn 95, Issue 1, 2006, Pages 17-27

  Contessa, Joseph N ^a,b   Abell, Angela ^a   Mikkelsen, Ross B ^a   Valerie, Kristoffer ^a   Schmidt Ullrich, Rupert K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apoptosis; c Src; EGFR; ErbB3 Her3

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MUTANT PROTEIN; PROTEIN BCL XL; PROTEIN TYROSINE KINASE;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; DELETION MUTANT; DIMERIZATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IONIZING RADIATION; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RADIATION PROTECTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STIMULATION;

ADENOVIRIDAE; BREAST NEOPLASMS; CELL SURVIVAL; COBALT RADIOISOTOPES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RADIATION TOLERANCE; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 32444446273     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9023-9     Document Type: Article

References (48)

1. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002
2. Nahta R, Hortobagyi GN, Esteva FJ: Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8: 5-17, 2003
3. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson S, Di Fiore P, Kraus M: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene : 1813-1821, 1995
4. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE: ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274: 17209-17218, 1999
5. Sweeney C, Carraway 3rd. KL: Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19: 5568-5573, 2000
6. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997
7. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science : 237-178-82, 1987
8. Sierke SL, Cheng K, Kim HH, Koland JG: Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J. 322: 757-763, 1997
9. Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C, Daly RJ: Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem 273: 7717-7724, 1998
10. Hellyer N, Kunrong C, Koland J: Erb-b3 (Her 3) Interaction with the p85 regulatory subunit of phosphoinositide 3 kinase. Biochem J 333: 757-763, 1998
11. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517, 2003
12. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773, 2002
13. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11: 495-505, 2003
14. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787, 2002
15. Cho HS, Leahy DJ: Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297: 1330-1333, 2002
16. Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669-672, 2002
17. Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J: A dominant negative mutation supresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol 11: 1454-1463, 1991
18. Redemann N, Holzmann B, von Ruden T, Wagner EF, Schlessinger J, Ullrich A: Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 12: 491-498, 1992
19. Qian X, O'Rourke DM, Fei Z, Zhang HT, Kao CC, Greene MI: Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. J Biol Chem 274: 574-583, 1999
20. Jones FE, Stern DF: Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18: 3481-3490, 1999
21. Spivak-Kroizman T, Rotin D, Pinchasi D, Ullrich A, Schlessinger J, Lax I: Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J Biol Chem 267: 8056-8063, 1992
22. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI: Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci USA 91: 1500-1504, 1994
23. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, Schmidt-Ullrich RK: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21: 4032-4041, 2002
24. Schmidt-Ullrich Contessa RK JN, Lammering G, Amorino G, Lin PS: ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22: 5855-5865, 2003
25. Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158, 2002
26. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ: Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20: 465-475, 2001
27. Tice D, Biscardi J, Nickles A, Parsons S: Mechanisms of biological synergy between cellular Src and EGFR. Proc Nat Acad Sci 96: 1415-1420, 1999
28. Karni R, Jove R, Levitzki A: Inhibition of pp60c-Src reduces Bel-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18: 4654-4662, 1999
29. Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18: 3440-3451, 1999
30. Valerie K, Brust D, Farnsworth J, Amir C, Taher MM, Hershey C, Feden J: Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther 7: 879-884, 2000
31. Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK: Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys 51: 775-784, 2001
32. Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen R, Valerie K, Lammering G, Amir C, Schmidt-Ullrich R: The relative role of Erb-b1-4 RTKs in radiation signal transduction of human carcinoma cells. Oncogene 20: 1388-1397, 2001
33. Jove R, Hanafusa T, Hamaguchi M, Hanafusa H: In vivo phosphorylation states and kinase activities of transforming p60c-src mutants. Oncogene Res 5: 49-60, 1989
34. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002
35. Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA: Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J 19: 4632-4643, 2000
36. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y: A hierarchical network of inter-receptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996
37. Kim HH, Sierke SL, Koland JG: Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 269: 24747-24755, 1994
38. Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550-3558, 1994
39. Deb TB, Su L, Wong L, Bonvini E, Wells A, David M, Johnson GR: Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF. J Biol Chem 276: 15554-15560, 2001
40. Walker F, Kato A, Gonez LJ, Hibbs ML, Pouliot N, Levitzki A, Burgess AW: Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol Cell Biol 18: 7192-7204, 1998
41. Wright JD, Reuter CW, Weber MJ: An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors. J Biol Chem 270: 12085-12093, 1995
42. Bjorge JD, Jakymiw A, Fujita DJ: Selected glimpses into the activation and function of Src kinase. Oncogene 19: 5620-5635, 2000
43. Martin SG: The Hunting of the SrcNature. Rev Mol Cell Biol 2: 467-475, 2001
44. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090-5101, 2001
45. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002
46. Naidu R, Yadav M, Nair S, Kutty MK: Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78: 1385-1390, 1998
47. Bobrow LG, Millis RR, Happerfield LC, Gullick WJ: c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur J Cancer 33: 1846-1850, 1997
48. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116-1121, 1992